Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
Condition or disease
HIV InfectionsHIV Seronegativity
Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Volunteers may be eligible for this study if they:
Are 20 to 60 years old.
Have used intravenous drugs in the previous 12 months.
Are available and commit to 3 years of follow-up.
Have a Thai National ID or its equivalent such as government official ID or state enterprise ID.
Are able to understand the study and pass a test showing they understand it, and give written informed consent.
Volunteers will not be eligible for this study if they:
Have a serious disease or condition, or history of a serious disease or condition such as lymphoma, that would interfere with the study.
Have ever received an experimental HIV-1 vaccine.
Have had or expect to have any treatments or medications that interfere with the immune system (e.g., long-term use of systemic steroids, chemotherapy, or radiation).
Have received a vaccine or immunoglobulin within 2 weeks of receiving the first study injection, or other vaccines within 4 weeks of the first study injection.
Have received immunoglobulins for a long time.
Have received non-licensed, research agents within 4 weeks of the first study injection.
Expect to miss study visits or plan to move within 36 months.
Are pregnant or breast-feeding or plan to become pregnant during the 36-month study period.
Are women who have sex with men and do not plan to use effective birth control.